ELVN vs ACAD โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ACAD Captures Institutional Edge (2โ2 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Acadia Pharmaceuticals Inc. (ACAD) driven by superior Valuation, Growth & Margin while ELVN counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, ELVN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ACAD at 17.8x Forward P/E and 10.2% operating margin (+22.8% YoY). In options structure, ELVN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro) against ACAD sits in BREAKDOWN (4th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ELVN | ACAD | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.6B | $3.1B | Larger Scale | ELVN |
| Trailing P/E Ratio Valuation | N/M | 8.6x | Lower Multiple | ACAD |
| Forward P/E Ratio Valuation | N/M | 17.8x | Lower Multiple | ACAD |
| Revenue Growth (YoY) Growth | +0.0% | +22.8% | Higher Growth | ACAD |
| Operating Margin (TTM) Profitability | 0.0% | 10.2% | Higher Margin | ACAD |
| Net Profit Margin Profitability | 0.0% | 30.1% | Higher Margin | ACAD |
| Return on Equity (ROE) Capital Efficiency | -16.8% | 31.4% | Higher ROE | ACAD |
| 52-Week Range Position Momentum | 69% ($15โ$62) | 21% ($16โ$31) | Stronger Trend | ELVN |
| Beta / 30D Volatility Risk Regime | 0.96ฮฒ ยท 60% Vol | 0.11ฮฒ ยท 93% Vol | Lower Realized Risk | ELVN |
| Unified Institutional Score Composite Signal | 35.9 / 100 (SELL) | 46.7 / 100 (HOLD) | Higher Composite | ACAD |